help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dimaraki, E. V.
Right arrow Articles by Jaffe, C. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dimaraki, E. V.
Right arrow Articles by Jaffe, C. A.
Right arrowPubmed/NCBI databases
*OMIM
*Compound via MeSH
*Substance via MeSH
Medline Plus Health Information
*Cushing's Syndrome
*Steroids
Hazardous Substances DB
*DEXAMETHASONE
*ERYTHROMYCIN
*HYDROCORTISONE
The Journal of Clinical Endocrinology & Metabolism Vol. 88, No. 7 3113-3116
Copyright © 2003 by The Endocrine Society

Troglitazone Induces CYP3A4 Activity Leading to Falsely Abnormal Dexamethasone Suppression Test

Eleni V. Dimaraki and Craig A. Jaffe

Department of Internal Medicine, Division of Endocrinology and Metabolism, University of Michigan (E.V.D., C.A.J.), and Department of Veterans Affairs Medical Center (C.A.J.), Ann Arbor, Michigan 48109

Address all correspondence and requests for reprints to: Craig A. Jaffe, M.D., 3920 Taubman Center, Box 0354, Ann Arbor, Michigan 48109. E-mail: cjaffe{at}umich.edu.


   Abstract
Top
 Abstract
Introduction
 Subjects and Methods
 Results
 Discussion
 References
 
After evaluating a patient who appeared to have a falsely abnormal response to the dexamethasone suppression test while taking troglitazone, we examined the effects of troglitazone on the activity of hepatic CYP3A4 and the screening tests for Cushing’s syndrome. We studied five healthy women and three healthy men, aged 25 ± 2 yr, before and after treatment with troglitazone (600 mg daily) for 28 d. Baseline 0800 h cortisol and corticosterone were similar before and after troglitazone treatment. Before troglitazone treatment, all subjects suppressed 0800 h cortisol below 1.8 µg/dl (mean, 0.66 ± 0.08 µg/dl) during the 1-mg overnight dexamethasone suppression test (DST), whereas during troglitazone treatment none of the subjects suppressed 0800 h cortisol below 1.8 µg/dl (mean, 9.0 ± 1.8 µg/dl). Serum dexamethasone levels decreased by 66 ± 4%, and the erythromycin breath test measurements increased by 27 ± 8%, indicating increased CYP3A4 activity during troglitazone treatment. The hydrocortisone suppression test (HST) was performed by administering 50 mg hydrocortisone at 2300 h. Using the criterion of suppression of 0800 h plasma corticosterone by more than 50%, the specificity of the HST was 100% both before and after troglitazone treatment. In conclusion, troglitazone induced the activity of CYP3A4 leading to falsely abnormal DST. HST is a useful alternative to the DST in patients taking medications that increase the activity of CYP3A4.


   Introduction
Top
 Abstract
 Introduction
Subjects and Methods
 Results
 Discussion
 References
 
THE OVERNIGHT 1-mg dexamethasone suppression test (DST) is widely used as a screening test for Cushing’s syndrome. Suppression of 0800 h serum cortisol below 1.8 µg/dl is considered a normal response, and failure to suppress serum cortisol below this level is highly suggestive of Cushing’s syndrome (1). The test can be falsely abnormal in several conditions that affect either cortisol secretion or the metabolism of dexamethasone (2, 3, 4, 5, 6, 7, 8).

Dexamethasone is primarily metabolized by hepatic CYP3A4 (9), an enzyme complex that is responsible for the metabolism of many xenobiotics (10, 11). Multiple xenobiotics are known to modify CYP3A4 activity (10, 11). In the 1960s it was observed that the antiepileptic diphenylhydantoin resulted in false positive DST (3, 8). Subsequently, several medications, including antiepileptics phenobarbital, primidone, ethosuximide, carbamazepine, and rifampin, have been shown to have a similar effect on DST by inducing the activity of CYP3A4 (4, 12, 13, 14, 15).

The FDA approved the antidiabetic agent troglitazone for use in patients with type 2 diabetes mellitus in 1997. It was eventually withdrawn from the market in the United States in March 2000 because of liver toxicity. Many of the patients who were receiving troglitazone were obese and also had hypertension, a constellation of findings that raises the possibility of Cushing’s syndrome. In addition, troglitazone was studied in clinical trials for the treatment of polycystic ovary syndrome, another condition that frequently needs to be differentiated from Cushing’s syndrome (16, 17).

In 1998 we evaluated a patient with the diagnosis of polycystic ovary syndrome who was participating in a clinical trial on the use of troglitazone for the treatment of this condition. She had clinical signs suggestive of Cushing’s syndrome. Twice she underwent a 1-mg overnight dexamethasone suppression test, and both times she failed to suppress her morning cortisol level. However, the 24-h urinary free cortisol level was within the normal range. We suspected that the DST was falsely abnormal because of induction of CYP3A4 by troglitazone. At that time, there was indirect evidence of CYP3A4 induction by troglitazone (Rezulin package insert) (17, 18, 19, 20, 21). As troglitazone was used in a patient population very likely to be screened for Cushing’s syndrome, we decided to study the effects of troglitazone on CYP3A4 systematically. We tested the effect of troglitazone on the activity of CYP3A4 and the results of the DST in eight healthy subjects. At the same time we have reexamined the value of alternative suppression tests for the screening for Cushing’s syndrome.


   Subjects and Methods
Top
 Abstract
 Introduction
 Subjects and Methods
Results
 Discussion
 References
 
Subjects

The study was approved by the Institutional Review Board and the General Clinical Research Center of University of Michigan. We studied eight healthy subjects, five women and three men (mean age, 25 ± 2 yr; mean body mass index, 23 ± 2 kg/m2). All subjects had normal screening laboratory tests, including liver function tests. The study was conducted from October 1998 until February 1999.

Study design

The subjects were studied twice, first at baseline and then in an identical protocol after treatment with troglitazone (600 mg daily) for 28 d. Troglitazone was continued while they completed the protocol, and compliance was assessed by counting the number of returned tablets at the end of the study. After an overnight fast, baseline serum cortisol, corticosterone, and 11-deoxycortisol were measured at 0800 h on d 1, and a [14C]erythromycin breath test (ERMBT) was performed at 0800 h on d 1 for the assessment of CYP3A4 activity (22, 23). An overnight hydrocortisone suppression test was performed by administering a single dose of hydrocortisone (50 mg) at 1100 h and measuring serum corticosterone, 11-deoxycortisol, and cortisol at 0800 h on d 2 as previously described (14). After a 1-d washout period, a DST was performed. Dexamethasone (1 mg) was taken at 1100 h on d 3, and serum cortisol and dexamethasone were measured on d 4.

Assays

Serum cortisol was measured by enzyme immunoassay (Diagnostic Systems Laboratories, Inc., Webster, TX). Serum corticosterone was measured by RIA after multiple solvent extractions, and serum 11-deoxycortisol and dexamethasone were measured by RIA after chromatography by Esoterix (Calabasas Hills, CA).

Data analysis

The normal response to DST was defined as an 0800 h serum cortisol suppression below 1.8 µg/dl (1). The normal corticosterone response to hydrocortisone was defined as a more that 50% suppression comparing to baseline, as previously described (14). The specificity of each test was calculated as the ratio of the number of subjects with normal response to the total number of subjects. Paired t tests were used to compare dexamethasone levels and the ERMBT results before and during troglitazone administration. Results are expressed as the mean ± SE.


   Results
Top
 Abstract
 Introduction
 Subjects and Methods
 Results
Discussion
 References
 
Baseline values

Baseline 0800 h serum cortisol was similar before and during troglitazone treatment (P = 0.66). The same was true for baseline serum corticosterone (P = 0.40), and 11-deoxycortisol (P = 1.0).

DST (Fig. 1Go)

In response to the 1-mg overnight DST, all subjects had 0800 h cortisol below 1.8 µg/dl (mean, 0.66 ± 0.08 µg/dl) before troglitazone treatment. During troglitazone treatment, 0800 h cortisol level after dexamethasone was above 1.8 µg/dl in all subjects (mean, 9.0 ± 1.8 µg/dl). Therefore, when the criterion of 0800 h cortisol suppression to below 1.8 µg/dl was used, the specificity of the DST in ruling out Cushing’s syndrome was 100% before treatment, but 0% during troglitazone treatment.



View larger version (15K):
[in this window]
[in a new window]
  		FIG. 1. The 0800 h plasma cortisol level during DST, before (left) and during (right) troglitazone treatment.

 
Serum dexamethasone levels after ingestion of dexamethasone at 1100 h decreased by 66 ± 4.4% during troglitazone treatment (171 ± 22 vs. 53 ± 5 ng/dl; P = 0.0015; Fig. 2Go)



View larger version (18K):
[in this window]
[in a new window]
  		FIG. 2. The 0800 h serum dexamethasone level after administration of dexamethasone at 2300 h, before and after troglitazone treatment.

 
Hydrocortisone suppression test (HST; Fig. 3Go)

Before treatment, after 50 mg hydrocortisone, 0800 h serum corticosterone levels decreased by more than 50% in all subjects (mean, -87 ± 2%). The corticosterone response to HST was similar during troglitazone treatment (-85 ± 5%; P = 0.91). Therefore, the specificity of the HST, using more than 50% suppression of 0800 h corticosterone as a criterion of normalcy, was 100% both before and during troglitazone treatment.



View larger version (15K):
[in this window]
[in a new window]
  		FIG. 3. The 0800 h plasma corticosterone suppression during HST, before (left) and during (right) troglitazone treatment.

 
After 50 mg hydrocortisone, serum 11-deoxycortisol at 0800 h was suppressed to less than 10 ng/dl in six of eight subjects at baseline and in all eight subjects during troglitazone treatment.

After hydrocortisone administration, before troglitazone treatment, 0800 h serum cortisol levels decreased below 5 µg/dl in five of seven subjects and by more than 50% of baseline in six of seven subjects, giving a specificity of 86%. During troglitazone treatment, 0800 h cortisol level decreased below 5 µg/dl in five of eight subjects and to below 50% of baseline in six of eight subjects, with a specificity of only 75%.

Erythromycin breath test (Fig. 4Go)

The activity of CYP3A4, as measured by the percentage of [14C]erythromycin exhaled at 20 min after radiolabeled erythromycin injection, increased during the troglitazone treatment by 27 ± 9% (P = 0.022).



View larger version (17K):
[in this window]
[in a new window]
  		FIG. 4. ERMBT results, indicating accelerated erythromycin metabolism during troglitazone treatment.

 

   Discussion
Top
 Abstract
 Introduction
 Subjects and Methods
 Results
 Discussion
References
 
In this study, we systematically investigated the effects of troglitazone on the activity of human CYP3A4, on the metabolism of dexamethasone, and on the DST. In addition, we examined the role of the previously described HST in the screening for Cushing’s syndrome in subjects receiving troglitazone. Although troglitazone has been withdrawn from clinical use, our data provide a useful model for the study of drug-induced increased CYP3A4 activity.

CYP3A4 is the most important drug-metabolizing P450 and is affected by a wide variety of commonly used medications. Induction of this enzyme leads to accelerated metabolism of a large number of xenobiotics, including cyclosporine, oral contraceptives, antibiotics, HMG-CoA reductase inhibitors, and corticosteroids, particularly dexamethasone. Induction of CYP3A4 results in false positive DST, because of accelerated metabolism of dexamethasone. In the case of troglitazone, the effects on the results of the DST were of particular importance because there is frequently a need to rule out Cushing’s syndrome in patients most likely to be taking troglitazone, such as obese patients with diabetes mellitus or obese women with polycystic ovary syndrome.

At the time this study was conducted there were only indirect data suggesting that troglitazone induced the activity of CYP3A4. The manufacturer reported decreased levels of terfenadine, ethinyl estradiol, and norethindrone when administered together with troglitazone (17). Decreased serum cyclosporine level in a patient receiving troglitazone had also been reported (19, 20). In our study, we used the ERMBT to directly assess the effects of troglitazone on CYP3A4 activity (22).

This test has been extensively validated and shown to reliably quantify the activity of CYP3A4 (23, 24, 25, 26, 27, 28). Although there is a large intersubject variability in the results of the ERMBT, the results for a given subject are remarkably consistent (22). Treatment with glucocorticoids or rifampicin increased the ERMBT values by 55% and 120%, respectively (22). In our subjects troglitazone increased CYP3A4 activity by 27%, verifying that the reported drug interactions of troglitazone were due to induction of CYP3A4 activity. Although this degree of induction was less than those reported for several other xenobiotics (20), it resulted in a clinically significant effect on dexamethasone. The serum dexamethasone levels 9 h after dexamethasone administration decreased by 66%, and false positive DST occurred in all subjects. Our findings are in agreement with a recent study that showed that the area under the curve of dexamethasone for 24 h after dexamethasone administration was decreased by 49% in subjects receiving troglitazone (29).

Our data are consistent with the effects of several other xenobiotics. Diphenylhydantoin, a well known inducer of CYP3A4, decreased the half-life of dexamethasone by 51% (2). Moreover, diphenylhydantoin resulted in abnormal 2-d, 2-mg DST or 1-mg, overnight DST (3, 14). Similarly, administration of rifampin resulted in low plasma dexamethasone concentrations and false positive 1-mg overnight DST (6).

Since our study was designed, there have been additional reports of clinically important effects of troglitazone on the metabolism of simvastatin, atorvostatin, and dexamethasone (29, 30, 31, 32). More direct evidence of troglitazone-induced CYP3A4 activity comes from in vitro studies using primary cell cultures of human hepatocytes (33). Troglitazone increased immunoreactive CYP3A4 protein, CYP3A4 mRNA, and testosterone 6ß-hydroxylase activity in a dose-dependent fashion (34). The in vitro ability of troglitazone to induce CYP3A4 was intermediate between those of rifampin and dexamethasone (34).

Our study also allowed us to investigate an alternative to the DST. This is of practical importance because many commonly used xenobiotics affect the activity of CYP3A4. In patients suspected of having a false positive DST result, 24-h urine collection for UFC would be an acceptable alternative. The sensitivity and specificity of this test are excellent (35). However, the use of 24-h UFC can be misleading in patients with episodic Cushing’s syndrome (36) as well as in patients with renal insufficiency (37). Late night salivary cortisol measurement is becoming a widely accepted and practical alternative and might eventually become the test of choice in screening for Cushing’s syndrome (33). However, the availability of well validated, alternative suppression tests would be useful, especially in cases of mild Cushing’s syndrome where the combination of different diagnostic tests is required.

One alternative is the HST, which was first described by Meikle et al. (14) in 1974. The HST takes advantage of the fact that the metabolism of hydrocortisone is minimally affected by the induction of CYP3A4 (2). The protocol tests the ability of hydrocortisone instead of dexamethasone to suppress pituitary ACTH secretion. An intermediate product of the steroid biosynthesis pathway that is ACTH dependant and can be measured without cross-reaction with hydrocortisone, such as corticosterone, is used as an indicator of ACTH suppression. Suppression of 0800 h plasma corticosterone to less than 50% of the baseline after receiving 50 mg hydrocortisone 9 h previously was considered normal.

In the first report of HST, the specificity of the test in patients treated with antiepileptic medications was excellent (14). Only 1 of 15 patients who was taking 3 different agents failed to suppress plasma corticosterone levels below 300 ng/dl. The HST was also performed in 3 patients with known Cushing’s syndrome, and all three failed to suppress serum corticosterone.

In our study, we have further explored the HST by measuring 11-deoxycortisol and serum cortisol levels. It was expected that serum 11-deoxycortisol, which is the immediate precursor of cortisol, would decrease after the administration of hydrocortisone. This was confirmed by our data. However, the use of 11-deoxycortisol did not offer any advantage over serum corticosterone. Interestingly, because of the short plasma half-life of hydrocortisone, we were able to detect a suppression of endogenous cortisol after hydrocortisone administration. However, the specificity of the HST was low when serum cortisol levels were used as the indicator of ACTH suppression.

Unlike troglitazone, the newer thiazolidinediones that are currently available for clinical use do not appear to significantly affect the activity of CYP3A4. In one clinical study rosiglitazone resulted in a small, not clinically significant, decrease in nifedipine concentrations, suggesting that rosiglitazone is a very weak inducer of CYP3A4 (38). In another study, rosiglitazone did not affect the metabolism of ethinyl estradiol and norethindrone (39). Pioglitazone had no effect on the area under the curve of dexamethasone (29). In the same study, troglitazone, but not pioglitazone, decreased the dexamethasone-induced hyperglycemia and hyperinsulinemia. Similarly, troglitazone decreased the plasma concentration of simvastatin, but pioglitazone had no effect (31). Therefore, the currently available thiazolidinediones would be unlikely to affect the results of DST.

In conclusion, we have shown that troglitazone specifically induces the activity of CYP3A4, resulting in accelerated metabolism of dexamethasone and a false positive 1-mg overnight DST. This effect is similar to that of antiepileptic medications and rifampin and gave us the opportunity to evaluate screening tests for Cushing’s syndrome. We have shown that the HST is a useful alternative to the DST in the setting of medications that affect CYP3A4 activity. However, the sensitivity and specificity of this test in patients with high clinical suspicion of Cushing’s syndrome remain to be determined.


   Footnotes
 
This work was supported by Parke-Davis Medical Research, Grant MO1-RR0042 (General Clinical Research Center), and the Research Service of the Department of Veterans Affairs.

Abbreviations: DST, Dexamethasone suppression test; ERMBT, [14C]erythromycin breath test; HST, hydrocortisone suppression test.

Received November 18, 2002.

Accepted April 1, 2003.


   References
Top
 Abstract
 Introduction
 Subjects and Methods
 Results
 Discussion
 References
 

  1. Newell-Price J, Trainer P, Besser M, Grossman A 1998 The diagnosis and differential diagnosis of Cushing’s syndrome and pseudo-Cushing’s states. Endocr Rev 19:647–672[Abstract/Free Full Text]
  2. Choi Y, Thrasher K, Werk Jr EE, Sholiton LJ, Olinger C 1971 Effect of diphenylhydantoin on cortisol kinetics in humans. J Pharmacol Exp Ther 176:27–34[Abstract/Free Full Text]
  3. Jubiz W, Meikle AW, Levinson RA, Mizutani S, West CD, Tyler FH 1970 Effect of diphenylhydantoin on the metabolism of dexamethasone. N Engl J Med 283:11–14
  4. Keitner GI, Fruzzetti AE, Miller IW, Norman WH, Brown WA 1989 The effect of anticonvulsants on the dexamethasone suppression test. Can J Psychiatry 34:441–443[Medline]
  5. Kobberling J, zur Muhlen AV 1973 The influence of diphenylhydantoin and carbamazepine on the circadian rhythm of free urinary corticoids and on the suppressibility of the basal and the "impulsive" activity by dexamethasone. Acta Endocrinol (Copenh) 72:308–318
  6. Kyriazopoulou V, Vagenakis AG 1992 Abnormal overnight dexamethasone suppression test in subjects receiving rifampicin therapy. J Clin Endocrinol Metab 75:315–317[Abstract]
  7. Werk EE, MacGee J, Sholiton LJ 1964 Effect of diphenylhydantoin on cortisol metabolism in man. J Clin Invest 43:1824–1835
  8. Werk Jr EE, Choi Y, Sholiton L, Olinger C, Haque N 1969 Interference in the effect of dexamethasone by diphenylhydantoin. N Engl J Med 281:32–34
  9. Gentile DM, Tomlinson ES, Maggs JL, Park BK, Back DJ 1996 Dexamethasone metabolism by human liver in vitro. Metabolite identification and inhibition of 6-hydroxylation. J Pharmacol Exp Ther 277:105–112[Abstract/Free Full Text]
  10. Li AP, Kaminski DL, Rasmussen A 1995 Substrates of human hepatic cytochrome P450 3A4. Toxicology 104:1–8[CrossRef][Medline]
  11. Guengerich FP 1999 Cytochrome P-450 3A4: regulation and role in drug metabolism. Annu Rev Pharmacol Toxicol 39:1–17[CrossRef][Medline]
  12. Privitera MR, Greden JF, Gardner RW, Ritchie JC, Carroll BJ 1982 Interference by carbamazepine with the dexamethasone suppression test. Biol Psychiatry 17:611–620[Medline]
  13. Robertson MM, Coppen A, Trimble MR 1986 The dexamethasone suppression test in medicated epileptic patients. Biol Psychiatry 21:225–228[CrossRef][Medline]
  14. Meikle AW, Stanchfield JB, West CD, Tyler FH 1974 Hydrocortisone suppression test for Cushing syndrome. Therapy with anticonvulsants. Arch Intern Med 134:1068–1071[Abstract/Free Full Text]
  15. Kyriazopoulou V, Parparousi O, Vagenakis AG 1984 Rifampicin-induced adrenal crisis in Addisonian patients receiving corticosteroid replacement therapy. J Clin Endocrinol Metab 59:1204–1206[Abstract/Free Full Text]
  16. Ehrmann DA, Schneider DJ, Sobel BE, Cavaghan MK, Imperial J, Rosenfield RL, Polonsky KS 1997 Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome. J Clin Endocrinol Metab 82:2108–2116[Abstract/Free Full Text]
  17. Dunaif A, Scott D, Finegood D, Quintana B, Whitcomb R 1996 The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome. J Clin Endocrinol Metab 81:3299–3306[Abstract]
  18. Loi CM, Stern R, Koup JR, Vassos AB, Knowlton P, Sedman AJ 1999 Effect of troglitazone on the pharmacokinetics of an oral contraceptive agent. J Clin Pharmacol 39:410–417[Abstract]
  19. Frantz RP, Nguyen TT 1998 Rezulin (troglitazone) greatly increases cyclosporine metabolism. J Heart Lung Transplant 17:1037–1038[Medline]
  20. Park MH, Pelegrin D, Haug III MT, Young JB 1998 Troglitazone, a new antidiabetic agent, decreases cyclosporine level. J Heart Lung Transplant 17:1139–1140[Medline]
  21. Koup JR, Anderson GD, Loi CM 1998 Effect of troglitazone on urinary excretion of 6ß-hydroxycortisol. J Clin Pharmacol 38:815–818[Abstract]
  22. Watkins PB, Murray SA, Winkelman LG, Heuman DM, Wrighton SA, Guzelian PS 1989 Erythromycin breath test as an assay of glucocorticoid-inducible liver cytochromes P-450. Studies in rats and patients. J Clin Invest 83:688–697
  23. Watkins PB 1994 Noninvasive tests of CYP3A enzymes. Pharmacogenetics 4:171–184[Medline]
  24. Watkins PB, Hamilton TA, Annesley TM, Ellis CN, Kolars JC, Voorhees JJ 1990 The erythromycin breath test as a predictor of cyclosporine blood levels. Clin Pharmacol Ther 48:120–129[Medline]
  25. Turgeon DK, Leichtman AB, Lown KS, Normolle DP, Deeb GM, Merion RM, Watkins PB 1994 P450 3A activity and cyclosporine dosing in kidney and heart transplant recipients. Clin Pharmacol Ther 56:253–260[Medline]
  26. Turgeon DK, Normolle DP, Leichtman AB, Annesley TM, Smith DE, Watkins PB 1992 Erythromycin breath test predicts oral clearance of cyclosporine in kidney transplant recipients. Clin Pharmacol Ther 52:471–478[Medline]
  27. Lown K, Kolars J, Turgeon K, Merion R, Wrighton SA, Watkins PB 1992 The erythromycin breath test selectively measures P450IIIA in patients with severe liver disease. Clin Pharmacol Ther 51:229–238[Medline]
  28. Lown KS, Thummel KE, Benedict PE, Shen DD, Turgeon DK, Berent S, Watkins PB 1995 The erythromycin breath test predicts the clearance of midazolam. Clin Pharmacol Ther 57:16–24[CrossRef][Medline]
  29. Morita H, Oki Y, Ito T, Ohishi H, Suzuki S, Nakamura H 2001 Administration of troglitazone, but not pioglitazone, reduces insulin resistance caused by short-term dexamethasone (DXM) treatment by accelerating the metabolism of DXM. Diabetes Care 24:788–789[Free Full Text]
  30. DiTusa L, Luzier AB 2000 Potential interaction between troglitazone and atorvastatin. J Clin Pharm Ther 25:279–282[CrossRef][Medline]
  31. Prueksaritanont T, Vega JM, Zhao J, Gagliano K, Kuznetsova O, Musser B, Amin RD, Liu L, Roadcap BA, Dilzer S, Lasseter KC, Rogers JD 2001 Interactions between simvastatin and troglitazone or pioglitazone in healthy subjects. J Clin Pharmacol 41:573–581[Abstract]
  32. Lin JC, Ito MK 1999 A drug interaction between troglitazone and simvastatin. Diabetes Care 22:2104–2106
  33. Papanicolaou DA, Mullen N, Kyrou I, Nieman LK 2002 Nighttime salivary cortisol: a useful test for the diagnosis of Cushing’s syndrome. J Clin Endocrinol Metab 87:4515–4521[Abstract/Free Full Text]
  34. Sahi J, Hamilton G, Sinz M, Barros S, Huang SM, Lesko LJ, LeCluyse EL 2000 Effect of troglitazone on cytochrome P450 enzymes in primary cultures of human and rat hepatocytes. Xenobiotica 30:273–284[CrossRef][Medline]
  35. Findling JW, Raff H 2001 Diagnosis and differential diagnosis of Cushing’s syndrome. Endocrinol Metab Clin North Am 30:729–747[CrossRef][Medline]
  36. Vagnucci AH, Evans E 1986 Cushing’s disease with intermittent hypercortisolism. Am J Med 80:83–88
  37. Issa BG, Page MD, Read G, John R, Douglas-Jones A, Scanlon MF 1999 Undetectable urinary free cortisol concentrations in a case of Cushing’s disease. Eur J Endocrinol 140:148–151[Abstract]
  38. Harris RZ, Inglis AM, Miller AK, Thompson KA, Finnerty D, Patterson S, Jorkasky DK, Freed MI 1999 Rosiglitazone has no clinically significant effect on nifedipine pharmacokinetics. J Clin Pharmacol 39:1189–1194[Abstract]
  39. Inglis AM, Miller AK, Culkin KT, Finnerty D, Patterson SD, Jorkasky DK, Freed MI 2001 Lack of effect of rosiglitazone on the pharmacokinetics of oral contraceptives in healthy female volunteers. J Clin Pharmacol 41:683–690[Abstract]



This article has been cited by other articles:


Home page
 Ther Adv Cardiovasc DisHome page
M. Collino, N. S.A. Patel, and C. Thiemermann
Review: PPARs as new therapeutic targets for the treatment of cerebral ischemia/reperfusion injury
Therapeutic Advances in Cardiovascular Disease, June 1, 2008; 2(3): 179 - 197.
[Abstract] [PDF]

Home page
 Toxicol SciHome page
M. A. Peraza, A. D. Burdick, H. E. Marin, F. J. Gonzalez, and J. M. Peters
The Toxicology of Ligands for Peroxisome Proliferator-Activated Receptors (PPAR)
Toxicol. Sci., April 1, 2006; 90(2): 269 - 295.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dimaraki, E. V.
Right arrow Articles by Jaffe, C. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dimaraki, E. V.
Right arrow Articles by Jaffe, C. A.
Right arrowPubmed/NCBI databases
*OMIM
*Compound via MeSH
*Substance via MeSH
Medline Plus Health Information
*Cushing's Syndrome
*Steroids
Hazardous Substances DB
*DEXAMETHASONE
*ERYTHROMYCIN
*HYDROCORTISONE

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals